FORSYTH DOUGLAS 4

What Happened

• Douglas Forsyth, a director of Inhibrx Biosciences (INBX), received an award of 15,000 derivative shares (stock options) on 2026-06-03. The reported exercise price is $0.00 and the filing lists the acquired amount as $0 (this is a grant, not an open-market purchase or sale).
• This is a grant of options/awarded derivative interests rather than an immediate purchase of common stock. No cash changed hands at grant.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Transaction type/code: Award/Grant (A) — derivative security (stock option).
• Amount granted: 15,000 option shares; reported acquisition price: $0.00; reported value: $0.
• Vesting/ exercisability: Per footnote F1, the option will be fully exercisable on June 3, 2027, subject to continued service through that date.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• No indication of a 10b5-1 plan, tax withholding, or a late filing in the supplied details.

Context

• Because this is a grant of options (derivative award) rather than a purchase of shares, it does not represent an immediate cash investment or sale by the insider. The grant typically aligns with compensation or retention programs and becomes economically meaningful only if/when the options vest and are exercised.
• Retail investors should treat awards as part of executive compensation; they do not by themselves signal immediate buying pressure.